Ann Johnson, OTR/L | |
1615 State 84 Nw, Backus, MN 56435 | |
(218) 682-3955 | |
Not Available |
Full Name | Ann Johnson |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 1615 State 84 Nw, Backus, Minnesota |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255424701 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 101774 (Minnesota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ann Johnson, OTR/L 1615 State 84 Nw, Backus, MN 56435 Ph: (218) 682-3955 | Ann Johnson, OTR/L 1615 State 84 Nw, Backus, MN 56435 Ph: (218) 682-3955 |
News Archive
Acceleron Pharma, a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy, a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength.
Originally, the label "borderline personality disorder" was applied to patients who were thought to represent a middle ground between patients with neurotic and psychotic disorders. Increasingly, though, this area of research has focused on the heightened emotional reactivity observed in patients carrying this diagnosis, as well as the high rates with which they also meet diagnostic criteria for posttraumatic stress disorder and mood disorders.
Following the successful integration of RIVA (Robotic IV Automation System) - a self-contained unit for filling IV syringes and bags - into three healthcare institutions in 2009, and the announcements of several more sales for installation in 2010, medical device company Intelligent Hospital Systems has confirmed the sale of three additional RIVA systems for cytotoxic drug preparation in 2010.
The use of flow-diverting stents to treat intracranial aneurysms appears safe and highly successful. Recently, however, there have been reports of ischemic complications occurring in brain territories supplied by the parent artery in which the stent is placed and in brain regions fed by small arterial branches whose ostia are covered by the stent.
› Verified 9 days ago